RDInvesting Provides Investors with Free In-Depth Equity Reports on ABMD, AMRI, ELGX and KERX


Follow this company

Companies Mentioned

NASDAQ:ABMD / NASDAQ:AMRI / NASDAQ:ELGX / NASDAQ:KERX
03/24/2014 [ACCESSWIRE]

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous s stock reports and market updates.

ABIOMED, Inc. (NASDAQ: ABMD) shares increased 2.44 percent to close at $26.84 a share Friday. The stock traded between $26.68 and $27.48 on volume of 790,665 shares traded. Analysts at BTIG have recently upgraded the company's rating to "buy" from "neutral". Shares of ABIOMED have gained approximately 0.5 percent year-to-date.

Find out more about ABIOMED including full access to the free equity report at:     
www.RDInvesting.com/ABMD

Albany Molecular Research, Inc. (NASDAQ: AMRI) shares declined 7.38 percent to close at $18.44 a share Friday. The stock traded between $17.18 and $19.10 on volume of 2.24 million shares traded. Analysts at Sterne Agee have recently downgraded the company's rating to "underperform" from "neutral". Shares of Albany Molecular Research have gained approximately 82.0 percent year-to-date.

Find out more about Albany Molecular Research including full access to the free equity report at:        
www.RDInvesting.com/AMRI

Endologix, Inc. (NASDAQ: ELGX) shares gained 0.77 percent to close at $13.06 a share Friday. The stock traded between $12.99 and $13.46 on volume of 3.03 million shares traded. Analysts at BTIG have recently upgraded the company's rating to "buy" from "neutral". Shares of Endologix have fallen approximately 25.0 percent year-to-date.

Find out more about Endologix including full access to the free equity report at:       
www.RDInvesting.com/ELGX

Keryx Biopharmaceuticals (NASDAQ: KERX) shares declined 1.13 percent to close at $14.84 a share Friday. The stock traded between $14.70 and $15.50 on volume of 3.87 million shares traded. Analysts at Mizuho have recently initiated coverage on the company with a "buy" rating and a price target of $25.00. Shares of Keryx Biopharmaceuticals have gained approximately 15.0 percent year-to-date.

Find out more about Keryx Biopharmaceuticals including full access to the free equity report at:       
www.RDInvesting.com/KERX

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:            
Research Driven Investing       
info@rdinvesting.com

COMMENTS

Leave a comment...
 * 

Your Name
 *